Pharmaceuticals

Ascentage Pharma Announces the Fifth Orphan Drug Designation Granted to Bcl-2 Inhibitor APG-2575 by the US FDA, and the Tenth Obtained by the Company

SUZHOU, China and ROCKVILLE, Md., Jan. 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug A...

2021-01-29 08:29 2138

RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals

TEL AVIV, Israel and RALEIGH, N.C., Jan. 28, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced a manufacturing agreement with Cosmo Pharmaceuticals NV (SIX: COPN) ("...

2021-01-28 22:03 5223

Immunoforge's 'PF1801' Is Designated as Orphan Drug by FDA

SEOUL, South Korea, Jan. 28, 2021 /PRNewswire/ -- Immunoforge, the company specializing in the development of new drugs for rare musculoskeletal diseases (Representatives: An Seong-Min and Jang Gi-Ho), announced that their new drug candidate PF1801 has been designated as the FDA orphan drug for t...

2021-01-28 22:00 1920

Clinical Trial of Proxalutamide's Trial of Hospitalized Covid-19 Patients Was Approved in Brazil

SUZHOU, China, Jan. 28, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the clinical trial (the "Trial") of Proxalutamide's treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board ("IRB") ofBrazil. The trial was accept...

2021-01-28 19:57 6256

Sai Life Sciences announces plans to double headcount and expand capabilities in Manchester, UK

MANCHESTER, England and HYDERABAD, India, Jan. 28, 2021 /PRNewswire/ -- Sai Life Sciences, one ofIndia's fastest growing Contract Research, Development & Manufacturing Organizations  (C...

2021-01-28 15:30 2894

Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 28, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142.HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal a...

2021-01-28 12:54 6582

Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease

DUBLIN, Jan. 28, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, announced today thatJapan's Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or intolerant chronic graft...

2021-01-28 09:00 4751

Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM

SHANGHAI and HONG KONG, Jan. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...

2021-01-28 08:00 2751

Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM

SHANGHAI and HONG KONG, Jan. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...

2021-01-28 08:00 4917

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

SAN DIEGO and BURLINGAME, California, Jan. 27, 2021 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, and Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical compa...

2021-01-27 20:00 4688

Sihuan Pharmaceutical (0460.HK): Xuanzhu Biopharm acquires Combio Pharmaceutical, the large-molecule integrated development platform helps drive innovation

HONG KONG, Jan. 27, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange Stock Code: 0460) is pleased to announce its innovation Xuanzhu Biopharma...

2021-01-27 11:21 6823

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO serv...

2021-01-27 08:26 6108

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerabili...

2021-01-26 05:05 3420

BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine

MAINZ, Germany and SHANGHAI, China, 25 Jan. 2021 /PRNewswire/ -- BioNTech SE  (Nasdaq: BNTX, "BioNTech" or "the Company") andShanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of ...

2021-01-26 01:18 5831

China Biologic Announces Extraordinary General Meeting of Shareholders

BEIJING, Jan. 25, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has called an extraordinary general meeting of shareholders (the "EGM...

2021-01-25 21:44 8976

BioVaxys Announces Initiation Of Cancer Vaccine EU Clinical Program, Completion Of BVX-0320 Preclinical Program

VANCOUVER, BC, Jan. 25, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021. BioVaxys is ple...

2021-01-25 21:00 3087

Boehringer Ingelheim named Top Employer in Malaysia, across Southeast Asia, and South Korea for 2021

KUALA LUMPUR, Malaysia, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inMalaysia and six other countries acrossAsia - Indonesia, Philippines, Singapore, South Korea, Thailand and Vietnam - by Top Employers Institute, the global authority on exce...

2021-01-25 10:00 2099

Boehringer Ingelheim named Top Employer in Vietnam, across Southeast Asia, and South Korea for 2021

HO CHI MINH CITY, Vietnam, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inVietnam and six other countries acrossAsia - Indonesia, Malaysia, Philippines, Singapore, South Korea andThailand - by Top Employers Institute, the global authority on ex...

2021-01-25 10:00 2244

Boehringer Ingelheim named Top Employer in Philippines, across Southeast Asia, and South Korea for 2021

MAKATI CITY, Philippines, Jan. 25, 2021 /PRNewswire/ --  Boehringer Ingelheim has been recognized as a Top Employer for 2021 inPhilippines and six other countries acrossAsia - Indonesia, Malaysia, Singapore, South Korea, Thailand and Vietnam - by Top Employers Institute, the global authority on ex...

2021-01-25 10:00 1983

Boehringer Ingelheim named Top Employer in Singapore, across Southeast Asia, and South Korea for 2021

SINGAPORE, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inSingapore and six other countries across Asia - Indonesia, Malaysia, Philippines, South Korea, Thailand and Vietnam - by Top Employers Institute, the global authority on excellence in peo...

2021-01-25 10:00 2369
1 ... 260261262263264265266 ... 313

Week's Top Stories